新兴的植物化学配方用于治疗类风湿性关节炎:一篇评论
Prachi Pimple1, Jenny Shah1, Prabha Singh1
1Department of Pharmaceutics, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle, Mumbai 400056, India.
Current drug delivery
|February 1, 2024
概括
风湿性关节炎 (RA) 管理正在通过天然植物化学物质发展. 纳米技术增强了这些植物衍生化合物,提高了它们在RA治疗中的有效性和生物可用性.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- 风湿性关节炎 (RA) 是一种慢性,T细胞介导的炎症性疾病,影响关节健康和生活质量.
- 目前的RA治疗包括疾病修饰性抗风湿药物 (DMARDs),NSAIDs,葡萄皮质类药物和生物DMARDs,有效性和副作用各不相同.
- 许多RA患者寻求替代疗法,常见的是草药治疗,这凸显了对新治疗策略的需求.
研究的目的:
- 审查植物衍生植物化学物质对类风湿性关节炎 (RA) 的治疗潜力.
- 探索纳米技术的应用在开发RA的先进植物化学配方.
- 讨论临床试验,监管考虑,挑战和基于植物化学物质的RA治疗的未来方向.
主要方法:
- 科学数据库的文献综述,重点关注RA,植物化学品和纳米技术.
- 对研究RA模型中植物化学物质抗炎和免疫调节作用的研究进行分析.
- 对植物化学品纳米配方的研究进行审查,以改善药物动力学特征和稳定性.
主要成果:
- 植物化学物质如类化合物,黄类化合物和多类化合物表现出与RA相关的抗炎和免疫调节特性.
- 植物化学品的局限性包括生物可用性,溶解性和稳定性差,这些可以通过纳米技术克服.
- 基于纳米技术的输送系统显著提高了植物化学品的吸收,稳定性和治疗效果.
结论:
- 植物化学物质作为RA的补充或替代治疗方法具有显著的前景.
- 纳米技术提供了一种可行的方法来提高RA管理中的植物化学品的临床实用性.
- 进一步的研究,临床试验和监管评估对于植物化学纳米配方成功转化为RA的临床实践至关重要.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K


